COVID-19 Antivirals Shionogi is actively expanding COVID-19 therapeutics with XOCOVA launched in the U.S. for post-exposure prevention, presenting a direct salesperson opportunity to engage hospitals, clinics, and public health agencies on antiviral distribution, reimbursement, and education.

Strategic Partnerships The company emphasizes collaborations with industry, government, biotech, and academia. Business development can target joint ventures, research collaborations, and sponsored trials to leverage Shionogi’s R&D network and accelerate product adoption.

Expansion & Acquisitions Recent investments and collaborations (Dioseve investment, research partnerships) indicate a growth-oriented portfolio. Opportunities exist to offer early-access programs, licensing talks, or co-development deals to expand pipeline reach.

Global Access Active presence across U.S. and China markets (Xinpuluo/Nadimethicone collaboration) suggests demand for distribution partnerships, payer engagement strategies, and market-entry support to scale access to therapies and vaccines.

Holistic Health Solutions Shionogi focuses on antimicrobial resistance, infectious diseases, neurology, oncology, and metabolic disorders. A multi-therapeutic approach allows cross-sell opportunities for related medicines, companion diagnostics, and clinical support services to healthcare providers.